Charles M. Baum
2016
In 2016, Charles M. Baum earned a total compensation of $3M as President and Chief Executive Officer at Mirati Therapeutics, a 32% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $163,920 |
|---|---|
| Option Awards | $2,260,494 |
| Salary | $546,155 |
| Other | $2,831 |
| Total | $2,973,400 |
Baum received $2.3M in option awards, accounting for 76% of the total pay in 2016.
Baum also received $163.9K in non-equity incentive plan, $546.2K in salary and $2.8K in other compensation.
Rankings
In 2016, Charles M. Baum's compensation ranked 3,227th out of 14,075 executives tracked by ExecPay. In other words, Baum earned more than 77.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,227 out of 14,075 | 77th |
Division Manufacturing | 1,116 out of 5,486 | 80th |
Major group Chemicals And Allied Products | 328 out of 1,900 | 83rd |
Industry group Drugs | 237 out of 1,543 | 85th |
Industry Pharmaceutical Preparations | 184 out of 1,173 | 84th |
Source: SEC filing on April 20, 2017.
Baum's colleagues
We found five more compensation records of executives who worked with Charles M. Baum at Mirati Therapeutics in 2016.
2016
Mark Gergen
Mirati Therapeutics
Former Executive Vice President and Chief Operations Officer
2016
James Christensen
Mirati Therapeutics
Chief Scientific Officer
2016
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
2016
Jamie Donadio
Mirati Therapeutics
Chief Financial Officer
2016
Chris LeMasters
Mirati Therapeutics